Highnoon likely to reach Rs1,121 with 54% upside

March 11, 2026 (MLN): Highnoon Laboratories is likely to reach a December 2026 target price of Rs1,121 per share, implying a total return potential of 54.3%, including an expected dividend yield of around 6%, according to Topline Securities.

Based on forward projections, the company is currently trading at a 2026 estimated price-to-earnings (P/E) multiple of 9.15x, which is significantly lower than its 10-year average P/E of 16.28x and the current sector P/E of 14.44x, suggesting meaningful valuation upside.

Strong long-term growth, industry outperformance

Highnoon has demonstrated consistent outperformance against both the broader pharmaceutical sector and the overall market across long-term horizons.

Over the past decade, the company’s revenue increased from Rs3.7bn in 2014 to Rs24.6bn in 2024, translating into a 10-year compound annual growth rate (CAGR) of 21%, compared with 15% for the industry.

In dollar terms, the company’s 10-year revenue CAGR stood at 9%, significantly higher than the industry average of 4%, showing strong operational execution and growth resilience despite currency volatility.

Margin strength, pricing power

Highnoon has maintained structurally superior profitability, supported by strong pricing power, an optimized product mix, and disciplined cost management.

The company’s five-year average gross margin stands at around 50%, significantly higher than the industry average of approximately 34%.

Notably, during the period of sharp PKR depreciation between 2022 and 2023, when industry margins came under severe pressure, Highnoon managed to preserve its profitability.

Gross margins during this period were recorded at 53% and 48%, compared with around 28% for the industry.

In 9M2025, margins further improved to 55%, and analysts expect them to remain elevated in the 54%–57% range during 2026–2030.

On a trailing twelve-month basis, the company’s gross margin stands near 55% compared with about 41% for the sector, while net margins are approximately 13% versus the industry average of 9%.

Chronic portfolio driving stability

A major driver of Highnoon’s consistent performance has been its high exposure to chronic therapies, which account for roughly 47% of its portfolio.

Chronic treatment segments provide greater revenue visibility, recurring prescriptions, and stronger pricing power, while also reducing seasonality risks.

The company’s top ten brands contribute approximately 50% of total revenue and around 47% of total volumes, providing strong scale advantages and brand-driven pricing discipline.

Key brands supporting growth

Highnoon’s portfolio includes several leading pharmaceutical brands that collectively drive revenue and market presence.

Major brands include Combivair, Cyrocin, Tagipmet, Misar, Kestine, Ulsanic, Tres Orix, Forge Family, Ceftro, and Skilax, which together contribute more than half of total gross revenue.

Combivair remains a core pillar in the respiratory segment, accounting for around 5% of total volumes and 7% of sales value, supported by strong physician preference and patient adherence.

Cyrocin supports the anti-infective segment and contributes 9% of volumes and 8% of sales value, reflecting strong demand in both hospital and outpatient settings.

Similarly, the Forge Family (Triforge and Biforge) strengthens Highnoon’s position in cardiology therapies, contributing around 6% of total sales value.

Other brands including Misar, Kestine, Ulsanic, and Tres Orix collectively contribute nearly 19% of both volumes and revenue, reflecting diversified therapeutic coverage.

Pricing, volume growth outlook

According to Topline Securities, Highnoon has delivered volumetric growth of around 5% CAGR between 2020 and 2024, alongside a pricing CAGR of approximately 12%, showing disciplined price realization and strong product mix management.

For the 2026–2030 period, volume growth is expected to accelerate to around 4–5%, while pricing growth is projected at 9–10%, supported by continued focus on non-controlled drug segments and effective price pass-through mechanisms.

The company is also expected to maintain revenue growth of around 12% CAGR during 2026–2030, supported by product launches, capacity expansion, and export growth.

Project FORCE to expand manufacturing capacity

Highnoon recently initiated Project FORCE, a greenfield pharmaceutical manufacturing expansion aimed at strengthening its production capacity and export capabilities.

The project involves establishing a state-of-the-art manufacturing facility at the Quaid-e-Azam Business Park Special Economic Zone (SEZ) in Sheikhupura, spread over 12 acres of land.

The facility will meet international regulatory standards and is expected to benefit from a 10-year tax exemption under SEZ incentives.

The expansion is expected to enhance long-term profitability by supporting export growth, higher volumes, and product diversification.

Healthy balance sheet, strategic expansion

Highnoon has continued to invest steadily in fixed assets to support its growth strategy.

The company’s operating fixed assets increased to Rs3.6 billion in 2024 from Rs2.8bn in 2023, while capital work-in-progress stood at Rs722m in 2023 before being capitalized.

These investments have largely been financed through internal cash generation, as the company retained around Rs1.2–1.3bn annually after dividend payouts, broadly matching its typical annual capital expenditure requirements.

The company maintains a very low debt-to-equity ratio of around 0.06x, providing ample financial flexibility to fund future expansion.

In February 2026, Highnoon also informed the Pakistan Stock Exchange that it is evaluating a potential acquisition, which could expand its business footprint, strengthen its product portfolio, and create operational synergies.

Strong dividend track record

Highnoon has consistently delivered strong shareholder returns through dividends. The company’s 10-year average payout ratio stands at around 47%, with a dividend CAGR of nearly 30% over the same period.

Over the last decade, Highnoon has returned approximately Rs7bn to shareholders, showing robust cash flow generation and disciplined capital allocation.

According to Topline Securities, the company is expected to pay dividends of around Rs45 per share in 2026 and Rs52 per share in 2027, translating into dividend yields of approximately 6% and 7%, respectively.

Growing export footprint

Highnoon has steadily expanded its international presence and now ranks among the leading listed pharmaceutical exporters in Pakistan, holding the fourth position with an export market share of about 12% as of 9M2025.

Export revenues reached approximately Rs1.5 billion during 9M2025, accounting for around 7% of total sales. Over the past decade, the company has achieved an export CAGR of roughly 24%, significantly outperforming the industry average export growth of around 13%, according to Topline Securities.

The company currently exports to multiple international markets, including Afghanistan, UAE, France, Kenya, Iraq, Cambodia, Tanzania, Sudan, Azerbaijan, Kyrgyzstan, and Ghana, reducing reliance on the domestic market while tapping demand for quality generics in emerging economies.

Strategic partnership to strengthen portfolio

Highnoon has also entered into a strategic partnership with Beximco Pharmaceuticals of Bangladesh, a globally accredited pharmaceutical manufacturer with regulatory approvals in major markets including the United States, European Union, Canada, Australia, and Brazil.

The collaboration focuses on distribution and marketing of specialized pharmaceutical products in Pakistan, particularly targeting high-burden therapeutic areas such as respiratory diseases, diabetes, and cardiovascular treatments. The partnership is expected to support marketing income growth and portfolio diversification.

Key risks

Key risks to the investment outlook include lower-than-expected volumetric growth, sharp depreciation of the Pakistani rupee against the US dollar, volatility in raw material and active pharmaceutical ingredient (API) costs, and potential supply chain disruptions or import restrictions.

Despite these risks, Highnoon’s strong brand portfolio, chronic therapy exposure, export expansion, and capacity investments position the company to sustain growth above industry averages in the coming years.

Copyright Mettis Link News